UCB has presented the first pooled data analysis from phase 3 trials of its bimekizumab treatment for moderate to severe hidradenitis suppurativa at the European Academy of Dermatology and Venereology (EADV) Congress. The analysis showed the treatment led to clinically important improvements and a large percentage of patients who achieved a high skin response after 16 weeks maintained their response up to 48 weeks.
Danger! DeepSek Can Help Cybercriminals Develop Malware
Tenable Research has found that chatbot DeepSek R1 can be manipulated into creating malware, increasing security risks. DeepSek was tricked into generating log-encrypting keyloggers and
